Xolair
Roche shares data from phase 3 trial of Xolair as allergy treatment
February 26, 2024Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …
Novartis’ Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps
August 6, 2020Sales and Marketing Novartis, Xolair, rhinosinusitis
Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the …
Novartis’ ligelizumab tops Xolair in chronic spontaneous urticaria
January 9, 2020Research and Development Novartis, Xolair, ligelizumab
Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair …
Novartis’ Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria
September 18, 2017Research and Development, Sales and Marketing Novartis, Xolair, chronic spontaneous urticarial, pharma, pharmaceutical
Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …
NICE approves Roche’s Gazyvaro and Novartis’ Xolair
March 11, 2015Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab
NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …
NICE wants more Xolair data
November 19, 2014Sales and Marketing Genentech, NHS, NICE, Novartis, UK, Xolair, hives, omalizumab
Novartis has been asked in draft guidance to give NICE more information before the watchdog can recommend its veteran asthma …
Xolair gets FDA approval for skin condition
March 24, 2014Research and Development, Sales and Marketing FDA, Novartis, Roche, Sanofi, Xolair, chronic hives, csu
An asthma drug developed by Roche subsidiary Genentech and Novartis has been granted an additional indication to treat chronic hives …
NICE decides Xolair is not value for money
August 12, 2010Sales and Marketing NICE, Novartis, Xolair
NICE has refused to back the use of Novartis’ Xolair for young children, saying the asthma drug’s cost brings little …
NICE rejects Xolair for children
June 3, 2010Sales and Marketing NICE, Xolair, asthma
The drug was first approved in Europe in November 2005 for patients aged 12 or older, and gained NICE approval …
NICE says yes to asthma treatment Xolair
September 6, 2007Sales and Marketing Xolair
Xolair, a drug which helps control the most severe cases of allergic asthma, has been approved for use on the …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
